| Symbol | GCTK |
|---|---|
| Name | GLUCOTRACK, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 301 RTE. 17 NORTH,,STE. 800, RUTHERFORD, New Jersey, 07070, United States |
| Telephone | +201 842 7715 |
| Fax | — |
| — | |
| Website | https://www.glucotrack.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001506983 |
| Description | GlucoTrack Inc, former Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack Model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto ones earlobe and connected to a small, handheld control and display unit, all without drawing blood. Additional info from NASDAQ: |
(88% Neutral) GLUCOTRACK, INC. (GCTK) Announces Enrollment Update for progress Due to Patient Enrollment Issues, Regulatory Process
Read moreGlucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Read moreGlucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Read moreNew Form POS AM - Glucotrack, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001493152-26-019677 <b>Size:</b> 466 KB
Read more(80% Positive) GLUCOTRACK, INC. (GCTK) Announces Enrollment Update for highlights Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreGlucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Read more(90% Positive) GLUCOTRACK, INC. (GCTK) Announces Enrollment Update for study Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreGlucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Read more